Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.
Hirut Yadeta TureNan Young LeeNa Ri KimEon Jeong NamPublished in: Vascular specialist international (2024)
Raynaud's phenomenon (RP) is a condition characterized by episodic, excessive vasoconstriction in the fingers and toes, triggered by cold or stress. This leads to a distinctive sequence of color changes in the digits. Pallor indicates reduced blood flow due to oxygen deprivation, while erythema appears as reperfusion. RP can be primary, with no identifiable underlying cause, or secondary, associated with other conditions. These conditions include autoimmune diseases, most commonly systemic sclerosis, vascular diseases; and neurological conditions. While the exact cause of RP remains unclear, genetic and hormonal (estrogen) factors are likely contributors. The pathogenesis of RP involves a complex interaction between the vascular wall, nerves, hormones, and humoral factors, disrupting the balance between vasoconstriction and vasodilation. In primary RP, the vascular abnormalities are primarily functional. However, in secondary RP, both functional and structural components occur in blood vessels. This explains why digital tissue damage frequently occurs in secondary RP but not primary RP. Diagnosis of RP is primarily clinical. Recent advancements in imaging techniques have aided in diagnosis and monitoring, but nail fold capillaroscopy remains the gold standard for distinguishing between primary and secondary RP. If there are signs of acute ischemic injury, vascular imaging, particularly preoperatively, is crucial to rule out other vaso-occlusive conditions. Management of RP focuses on alleviating symptoms and preventing tissue damage. Vasodilator medications are the first-line treatment when general measures like warmth and stress management are not sufficient. Dihydropyridine calcium channel blockers (CCBs), such as nifedipine, are commonly used for vasodilation. Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage. Bosentan, an endothelin-1 receptor antagonist, has shown effectiveness in treating and preventing digital ulcers, especially in patients with multiple ulcers. For severe cases, botulinum toxin injections or sympathectomy surgery can be used to control RP symptoms. However, botulinum toxin injections require repeated administration, and sympathectomy's long-term effectiveness is uncertain. Fat grafting is a promising surgical therapy for promoting healing and preventing tissue injury.
Keyphrases
- systemic sclerosis
- botulinum toxin
- blood flow
- oxidative stress
- randomized controlled trial
- high resolution
- rheumatoid arthritis
- cerebral ischemia
- acute myocardial infarction
- pulmonary arterial hypertension
- intensive care unit
- minimally invasive
- acute coronary syndrome
- metabolic syndrome
- physical activity
- sleep quality
- ischemia reperfusion injury
- brain injury
- pulmonary hypertension
- estrogen receptor
- weight loss
- mass spectrometry
- coronary artery bypass
- early onset
- blood brain barrier
- liver failure
- density functional theory
- mechanical ventilation
- angiotensin converting enzyme